Krensavage Asset Management, LLC - Q1 2017 holdings

$310 Million is the total value of Krensavage Asset Management, LLC's 15 reported holdings in Q1 2017. The portfolio turnover from Q4 2016 to Q1 2017 was 100.0% .

 Value Shares↓ Weighting
DSCI ExitDERMA SCIENCES INC$0-891,026
-100.0%
-1.66%
ExitINDIVIOR PLC$0-4,650,416
-100.0%
-6.08%
Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR filed 2017-05-15
Signatures

The EDGAR filing(s) were signed by:

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
UNITED THERAPEUTICS CORP36Q3 202318.1%
Enanta Pharmceuticals Inc35Q3 202316.7%
INVACARE CORP28Q3 20215.8%
RTI SURGICAL INC23Q2 20207.9%
MCKESSON CORP20Q3 202216.3%
BIOGEN INC19Q3 202316.0%
MERCK & CO. INC.18Q1 201911.1%
DIGIRAD CORP18Q1 20191.0%
REGENERON PHARMACEUTICALS16Q3 202316.1%
ALKERMES PLC16Q3 202314.1%

View Krensavage Asset Management, LLC's complete holdings history.

Latest significant ownerships (13-D/G)
Krensavage Asset Management, LLC Q1 2017 significant holdings filed using form 13D/G when ownership exceeds 5% of a company's total stock issue.
FiledShares Percentage
SURGALIGN HOLDINGS, INC.February 19, 20215,380,4496.6%
RTI SURGICAL, INC.February 14, 20193,852,5676.1%
Aviragen Therapeutics, Inc.February 15, 20182,292,0585.9%
ENANTA PHARMACEUTICALS INCFebruary 15, 2017883,9024.6%
Biota Pharmaceuticals, Inc.February 17, 20162,267,6555.9%

View Krensavage Asset Management, LLC's complete significant-ownership history.

Latest filings
TypeFiled
13F-HR2024-05-15
SCHEDULE 13G2024-02-27
13F-HR2024-02-14
13F-HR2023-11-15
13F-HR2023-08-11
13F-HR2023-05-16
13F-HR2023-02-15
13F-HR2022-11-15
13F-HR2022-08-16
13F-HR2022-05-17

View Krensavage Asset Management, LLC's complete filings history.

Compare quarters

Export Krensavage Asset Management, LLC's holdings